Melanoma researchers shine at the State's premier cancer awards ceremony

Melanoma researchers shine at the State's premier cancer awards ceremony

3 November 2017

Melanoma Institute Australia’s world-leading researchers have excelled at the 2017 Cancer Institute NSW’s Premier Awards for Outstanding Cancer Research.

Hosted by the Cancer Institute NSW, the Awards honour the achievements of individuals and teams working across the cancer research sector to lessen the impact of cancer on the people of NSW.

Leading researchers from MIA have been acknowledged with three prestigious awards for their excellence in melanoma research which is changing clinical practice and saving lives.  

MIA’s Conjoint Medical Directors, Professor Richard Scolyer and Professor Georgina Long, and their research team received the award for Excellence in Translational Cancer Research. The award recognises contributions having a lasting impact and demonstrating sustained progress against cancer.

The team has made key discoveries and transformed global melanoma patient care. Their discoveries range from defining new determinants of risk in primary melanoma which have impacted international reporting guidelines; development of diagnostic tests that have become clinical practice worldwide; identifying novel molecular phenotypes of melanoma; and leading development of novel treatments particularly in patients with advanced melanoma where there were no effective therapies previously.

Professor Richard Kefford AM has been named Outstanding Cancer Researcher of the Year. This prestigious award is given to an individual who has made an outstanding and sustained contribution to cancer research and has a record of substantive and noteworthy publications.

Professor Kefford’s research has played a seminal role in revealing the genetics of melanoma and he has authored more than 300 journal publications, chapters and books. He has been a Principal Investigator on more than 40 clinical trials exploring new immunotherapies that are transforming the treatment of melanoma. In addition, he has mentored a new generation of leading laboratory and clinical researchers in the field of cancer.

Professor Helen Rizos and the Melanoma Translational Research Team have won the Wildfire Highly Cited Publication Award. The award is given to researchers for a highly cited publication that is expected to significantly influence cancer control or further research. The publication that won Professor Rizos and the MIA team the award was published in Clinical Cancer Research and determined that first line combination therapies that target multiple pathways may have more success than an adaptive sequential approach. This publication has led to a new standard of care for patients with BRAF-mutant advanced melanoma being treated with combination BRAF and MEK inhibitors.

“We are extremely proud of our award winners but also our wide network of MIA-affiliated research teams,” said MIA’s CEO Carole Renouf. “The goal we all share is zero deaths from melanoma and we are making rapid progress towards cure.”

MIA’s Conjoint Medical Director Professor Richard Scolyer said, “The depth and breadth of research undertaken at MIA ensures that we are key players on the world stage of melanoma research. It is an honour to lead this organisation and I am delighted that our people are being recognised for their tremendous efforts.”

MIA’s Conjoint Medical Director Professor Georgina Long added, “The passionate people at MIA work tirelessly to consistently produce research that has a direct positive impact on the lives of patients and their families.”

Chief Cancer Officer and CEO of the Cancer Institute NSW, Professor David Currow said, “Ten years ago, people diagnosed with advanced melanoma had their life expectancy measured in months. Now, Australian people with melanoma have a range of increasingly personalised treatment options. This has seen response rates improve from less than 10 per cent with older chemotherapy to between 40 and 70 per cent today.

“I commend these researchers for their tireless efforts and congratulate them on their tremendous success in changing the way we treat these cancers.”

The awards ceremony was held on Friday 3rd November at the Four Seasons Hotel Sydney. Adam Spencer, as the Master of Ceremonies, joined more than 300 pre-eminent guests from the health and medical research sector to share successes and forge collaborations.

MIA's research pivotal in TGA's approval of new therapy
01 Feb 2016

MIA's research pivotal in TGA's approval of new therapy

Clinical research undertaken at MIA has been pivotal in supporting the recent Therapeutic Goods Administration approval of Opdivo (nivolumab) for advanced melanoma.

The Face of Melanoma March
28 Jan 2016

The Face of Melanoma March

Maddison, the face of our Melanoma March campaign, knows the far-reaching effects that melanoma can have.

Q&A With An Expert: Dermatologist
28 Jan 2016

Q&A With An Expert: Dermatologist

MIA's Dermatologist Associate Professor Pascale Guitera answers your most commonly-asked questions about sunscreen. 

New figures show melanoma most common cancer in young Queenslanders
08 Jan 2016

New figures show melanoma most common cancer in young Queenslanders

Statistics released by the Queensland Cancer Registry have revealed that melanoma is the most common cancer in young Queenslanders aged under 35, with rates in young women more than 20 per cent higher than in men.

5 minutes with Associate Professor Georgina Long
17 Dec 2015

5 minutes with Associate Professor Georgina Long

As 2015 draws to a close, we took the opportunity to speak with Associate Professor Georgina Long to discuss her crucial role at Melanoma Institute Australia, and the current research projects she is working on.

Watch Your Mate's Back: helping young Australians recognise melanoma
30 Nov 2015

Watch Your Mate's Back: helping young Australians recognise melanoma

MIA’s annual summer awareness campaign, which launched today (1 December), is reminding Australians how to protect themselves from the sun while highlighting the importance of encouraging friends, partners and family to do the same. 

Your Guide to Early Melanoma patient information packs
21 Oct 2015

Your Guide to Early Melanoma patient information packs

Your Guide to Early Melanoma is a new patient information pack to offer additional information for those affected by melanoma.   

Clinicians invited to MIA's 'World Round Up' event
21 Oct 2015

Clinicians invited to MIA's 'World Round Up' event

Special Event to share advances in diagnosis and treatment of both early and late stage melanoma

Melanoma landmark study to develop personalised cancer treatment
26 Aug 2015

Melanoma landmark study to help further develop personalised cancer treatment

MIA researchers contribute to the discovery of ‘treasure trove’ of information leading to more targeted treatments for melanoma 

Sunrise features inspiring story of MIA patient
10 Aug 2015

Sunrise features inspiring story of MIA patient

Melanoma Institute Australia (MIA) patient Tara Moran and her seven year old daughter Olivia, who is fundraising for MIA, have been in the national media spotlight this week. 

Leading researchers honoured for global contribution to science and innovation
16 Jul 2015

Leading researchers honoured for global contribution to science and innovation

Melanoma Institute Australia’s (MIA’s) researchers have again been recognised, this time in the prestigious line-up for the 2015 Thomson Reuters Australian Citation & Innovation Awards.

MIA welcomes ground-breaking new PBS melanoma treatment
03 Jul 2015

MIA welcomes ground-breaking new PBS melanoma treatment

New Federal Government funding means patients with the most deadly form of melanoma, will soon be able to receive treatment with the drug Keytruda® (pembrolizumab), on the Pharmaceutical Benefits Scheme (PBS).

MIA contributes to major research breakthrough which pioneers a new way of treating cancer
01 Jun 2015

MIA contributes to major research breakthrough which pioneers a new way of treating cancer

The best ever results seen in metastatic melanoma treatment have been presented at the International ASCO Conference.

Q&A with our Clinical Research Fellow
26 May 2015

Q&A with our Clinical Research Fellow

We sat down for a short Q&A with our Clinical Research Fellow Sangeetha Ramanujam

International Clinical Trials Day marked
20 May 2015

International Clinical Trials Day marked

Today marks International Clinical Trials Day held on May 20 each year celebrating how far clinicians have come in the field of research. 

5 minutes with Practice Manager Sherrie D'Souza
15 May 2015

5 minutes with Practice Manager Sherrie D'Souza

We sat down with MIA Practice Manager, Sherrie D'Souza and got an insight into the day of life of her role. 

Associate Professor Georgina Long has won the InStyle Women In Style Award
14 May 2015

Associate Professor Georgina Long has won the InStyle Women In Style Award

Dr Long was nomitated for the InStyle Women In Style Awards in the Science and Environment category. 

The Federal Government's 2015-16 Budget announcements benefit research
14 May 2015

The Federal Government's 2015-16 Budget announcements benefit research

The Federal Government’s 2015-16 Budget was announced this week with a boost for medical research funding. 

Professor Thompson made an honorary member of the American Surgical Association
01 May 2015

Professor Thompson made an honorary member of the American Surgical Association

The Association's members include prominent surgeons from around the world. 

MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients
20 Apr 2015

MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients

This is a landmark study, the first in a class of drugs that will change the future of treatment for all cancers.